SEC Tracker
Get the app

NRX Pharmaceuticals NRXP

NRX Pharmaceuticals announced FDA approval of its Ketamine ANDA

Item 7.01 Investor disclosure

Form
8-K
Filed
Importance
Routine
  1. FDA approved NRXP's ANDA for Preservative-Free Ketamine
  2. Approval came ahead of the November 10, 2026 goal date
  3. Company hosted a conference call on October 30, 2026

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when NRX Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. iBio IBIO public float $58M, Dec 31, 2025
  2. Sutro Biopharma STRO public float $60M, Jun 30, 2025
  3. PDS Biotechnology PDSB public float $60M, Jun 30, 2025
  4. Avalo Therapeutics AVTX public float $54M, Jun 30, 2025
  5. Medicinova MNOV public float $62M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.